Byrska, B; Zuba, D; Stanaszek, R. Determination of piperazine derivatives in “legal highs”. Probl. Forensic Sci., , 81, 101–113. 852 kB.
Maurer, HH. Mass spectra of select benzyl- and phenyl- piperazine designer drugs. Microgram J., 1 Jan 2004, 2 (1–4), 22–26. 326 kB.
Zuba, D; Byrska, B. Prevalence and co-existence of active components of ‘legal highs’. Drug Test. Anal., 1 Jun 2013, 5 (6), 420–429. 1.3 MB. https://doi.org/10.1002/dta.1365
Clark, CR; DeRuiter, J. Analytical and synthetic studies on designer drugs of the piperazine class, US DOJ, 1 Dec 2014. 15.6 MB. #4-OMePP
Nagai, F; Nonaka, R; Kamimura, KSH. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol., 22 Mar 2007, 559 (2), 132–137. 399 kB. https://doi.org/10.1016/j.ejphar.2006.11.075 #4MPP
Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry. Talanta, 15 Feb 2009, 77 (4), 1245–1272. 1.2 MB. https://doi.org/10.1016/j.talanta.2008.07.062 #4MPP
EMCDDA. New drugs in Europe, 2005, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2006. 1.2 MB. #MeOPP
Bishop, SC; McCord, BR; Gratz, SR; Loeliger, JR; Witkowski, MR. Simultaneous separation of different types of amphetamine and piperazine designer drugs by capillary electrophoresis with a chiral selector. J. Forensic Sci., 1 Mar 2005, 50 (2), 1–10. 597 kB. https://doi.org/10.1520/JFS2004239 #pMeOPP LC,MS,UV,other
Nishimura, Y; Tanaka, S; Ikeda, H; Yamazaki, Y. Study of method for identifying regioisomers of controlled drugs. JCCL, 1 Dec 2015, (55), 65–85. 707 kB. #4-MPP Japanese, English abstract GC,MS,UV
Åstrand, A; Guerrieri, D; Vikingsson, S; Kronstrand, R; Green, H. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors—On-target receptor potency and efficacy, and off-target effects. Forensic Sci. Int., 1 Dec 2020, 317 110553. 1.7 MB. https://doi.org/10.1016/j.forsciint.2020.110553 #4-MeOPP
Seto, T; Takahashi, M; Nagashima, M; Suzuki, J; Yasuda, I. The identifications and the aspects of the commercially available uncontrolled drugs purchased between Apr. 2003 and Mar. 2004. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2005, 56 75–80. 1.2 MB. #4MPP MS,NMR,UV